Abstract
To identify target genes for the hemizygous deletions of chromosome 13 that are recurrently observed in malignant gliomas, we performed genome-wide DNA copy-number analysis using array-based comparative genomic hybridization and gene expression analysis using an oligonucleotide-array. The response gene to complement 32 (RGC32) at 13q14.11 was identified as a deletion target, and its expression was frequently silenced in glioma cell lines compared with normal brain. Levels of RGC32 mRNA tended to decrease toward higher grades of primary astrocytomas, especially in tumors with mutations of p53. Expression of RGC32 mRNA was dramatically increased by exogenous p53 in a p53-mutant glioma cell line, and also by endogenous p53 in response to DNA damage in p53+/+ colon-cancer cells, but not in isogenic p53−/− cells. Chromatin immunoprecipitation and reporter assays demonstrated binding of endogenous p53 protein to the promoter region of the RGC32 gene, implying p53-dependent transcriptional activity. Transiently and stably overexpressed RGC32 suppressed the growth of glioma cells, probably owing to induction of G2/M arrest. Immunocytochemical analysis revealed a concentration of RGC32 protein at the centrosome during mitosis. RGC32 formed a protein complex with polo-like kinase 1 and was phosphorylated in vitro. These observations implied a novel mechanism by which p53 might negatively regulate cell-cycle progression by way of this newly identified transcriptional target. Our results provide the first evidence that RGC32 might be a possible tumor-suppressor for glioma, that it is directly induced by p53, and that it mediates the arrest of mitotic progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, Rus V et al. (2002). RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem 277: 502–508.
Badea TC, Niculescu FI, Soane L, Shin ML, Rus H . (1998). Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem 273: 26977–26981.
Barr FA, Sillje HH, Nigg EA . (2004). Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429–440.
Burns KL, Ueki K, Jhung SL, Koh J, Louis DN . (1998). Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57: 122–130.
Dietzmann K, Kirches E, von Bossanyi P, Jachau K, Mawrin C . (2001). Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 53: 1–11.
el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B . (1992). Definition of a consensus binding site for p53. Nat Genet 1: 45–49.
Elez R, Piiper A, Giannini CD, Brendel M, Zeuzem S . (2000). Polo-like kinase1, a new target for antisense tumor therapy. Biochem Biophys Res Commun 269: 352–356.
Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7: 275–286.
Holland EC . (2001). Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 12: 120–129.
Imoto I, Yuki Y, Sonoda I, Ito T, Shimada Y, Imamura M et al. (2003). Identification of ZASC1 encoding a Kruppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas. Cancer Res 63: 5691–5696.
Inazawa J, Inoue J, Imoto I . (2004). Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 95: 559–563.
Inda MM, Fan X, Munoz J, Perot C, Fauvet D, Danglot G et al. (2003). Chromosomal abnormalities in human glioblastomas: gain in chromosome 7p correlating with loss in chromosome 10q. Mol Carcinog 36: 6–14.
Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S et al. (2004). Overexpression of PDZK1 within the 1q12–q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 165: 71–81.
Jongsma AP, Piek JM, Zweemer RP, Verheijen RH, Klein Gebbinck JW, van Kamp GJ et al. (2002). Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol Pathol 55: 305–309.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC et al. (2002). The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215–225.
Ko LJ, Prives C . (1996). p53: puzzle and paradigm. Genes Dev 10: 1054–1072.
Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG . (2001). Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61: 7683–7688.
Lane HA, Nigg EA . (1996). Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135: 1701–1713.
Liu X, Erikson RL . (2002). Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 99: 8672–8676.
Liu X, Erikson RL . (2003). Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100: 5789–5794.
Lu W, Takahashi H, Furusato M, Maekawa S, Nakano M, Meng C et al. (2006). Allelotyping analysis at chromosome 13q of high-grade prostatic intraepithelial neoplasia and clinically insignificant and significant prostate cancers. Prostate 66: 405–412.
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK et al. (2001). Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311–1333.
Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y et al. (2002). Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7: 1173–1182.
Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F et al. (2005). Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res 65: 10233–10242.
Miyashita T, Reed JC . (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299.
Mundt KE, Golsteyn RM, Lane HA, Nigg EA . (1997). On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem Biophys Res Commun 239: 377–385.
Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H . (2001). Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715–1719.
Nishizaki T, Ozaki S, Harada K, Ito H, Arai H, Beppu T et al. (1998). Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 21: 340–346.
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. (2000). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849–862.
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL et al. (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892–6899.
Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M et al. (2004). Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berlin) 108: 49–56.
Pan H, Califano J, Ponte JF, Russo AL, Cheng KH, Thiagalingam A et al. (2005). Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 65: 1664–1669.
Saigusa K, Hashimoto N, Tsuda H, Yokoi S, Maruno M, Yoshimine T et al. (2005). Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci 96: 676–683.
Sato T, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y . (1991). Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res 51: 5794–5799.
Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A et al. (2000). High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96: 1505–1511.
Sonoda I, Imoto I, Inoue J, Shibata T, Shimada Y, Chin K et al. (2004). Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res 64: 3741–3747.
Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K . (2002). Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863–1877.
Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H et al. (2005). Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 96: 100–110.
Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I . (2005). Polo-like kinases (Plks) and cancer. Oncogene 24: 287–291.
Tokino T, Thiagalingam S, el-Deiry WS, Waldman T, Kinzler KW, Vogelstein B . (1994). p53 tagged sites from human genomic DNA. Hum Mol Genet 3: 1537–1542.
Zhu Y, Parada LF . (2002). The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2: 616–626.
Acknowledgements
We thank Dr Bert Vogelstein (Howard Hughes Medical Institute, The Sidney Kimmel Comprehensive Cancer Center, and Program in Cellular and Molecular Medicine, The Johns Hopkins University Medical Institutions) for HCT116 (p53+/+) and HCT116 (p53−/−) cell lines and Dr Hideyuki Saya (Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Kumamoto University) for the anti-Aurora-A antibody. We also thank Ai Watanabe, Ayako Takahashi and Rumi Mori for technical assistance. This work was supported by Grants-in-Aid for Scientific Research on Priority Areas (C) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; by a Grant-in-Aid from Core Research for Evolutional Science and Technology (CREST) of the Japan Science and Technology Corporation (JST); and by 21st Century Center of Excellence Program for Molecular Destruction and Reconstitution of Tooth and Bone.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saigusa, K., Imoto, I., Tanikawa, C. et al. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene 26, 1110–1121 (2007). https://doi.org/10.1038/sj.onc.1210148
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210148
Keywords
This article is cited by
-
Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults
Leukemia (2022)
-
Integration of TGF-β-induced Smad signaling in the insulin-induced transcriptional response in endothelial cells
Scientific Reports (2019)
-
RGC-32 and diseases: the first 20 years
Immunologic Research (2019)
-
RGC32 induces epithelial-mesenchymal transition by activating the Smad/Sip1 signaling pathway in CRC
Scientific Reports (2017)
-
Response gene to complement 32 regulates the G2/M phase checkpoint during renal tubular epithelial cell repair
Cellular & Molecular Biology Letters (2016)